# Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer

> **NCT02842294** · — · UNKNOWN · sponsor: **Centre Hospitalier Universitaire de Besancon** · enrollment: 320 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer
- Quality of Life

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02842294
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-05
- **Primary completion:** 2017-02
- **Final completion:** 2018-02
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2016-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02842294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02842294, "Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02842294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*